Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Ebina, Y. Kimura, H. Ohta, S. Ohkouchi, S. Hisata, N. Hirota, T. Tamada, T. Nukiwa, Clinical Study Group of Pirfenidone in Japan (Sendai, Japan). Enhanced effects of pirfenidone on the early phase of idiopathic pulmonary fibrosis (IPF). Eur Respir J 2009; 34: Suppl. 53, 666

Member's Comments

No comment yet.

Related content which might interest you: Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 Does IFN-g slow progression of idiopathic pulmonary fibrosis (IPF)? Source: Eur Respir J 2005; 26: Suppl. 49, 335s Year: 2005 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Extended analysis of phase III trial of pirfenidone: More pronounced effect in mild impairment of patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2010 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2015 – IPF pathogenesis Year: 2015 Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Treatment of idiopathic pulmonary fibrosis (IPF) with pentoxifylline (POF) Source: Eur Respir J 2007; 30: Suppl. 51, 121s Year: 2007 Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Abnormal pulmonary arterial remodelling in patients with combined pulmonary fibrosis emphysema (CPFE) and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2011 - Clinical approach of diffuse parenchymal lung disease Year: 2011 Pharmacometabolic response to pirfenidone in pulmonary fibrosis detected by MALDI-FTICR-MSI Source: Eur Respir J, 52 (3) 1702314; 10.1183/13993003.02314-2017 Year: 2018 Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 Pulmonary vascular changes in COPD and idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2006 - Clinical physiology Year: 2006 Plasma protein signature of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2017 – ILDs: clinical aspects Year: 2017